| Original language | English (US) |
|---|---|
| Article number | 120086 |
| Journal | Journal of the neurological sciences |
| Volume | 432 |
| DOIs | |
| State | Published - Jan 15 2022 |
Keywords
- Antibody
- Breast cancer
- Encephalomyelitis
- Myelitis
- Spinal cord
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Paraneoplastic myelopathy with amphiphysin autoantibodies and lobular breast carcinoma in situ. / Alexandres, Christina A.; Tremblay, Matthew A.; Klassen, Christine L. et al.
In: Journal of the neurological sciences, Vol. 432, 120086, 15.01.2022.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Paraneoplastic myelopathy with amphiphysin autoantibodies and lobular breast carcinoma in situ
AU - Alexandres, Christina A.
AU - Tremblay, Matthew A.
AU - Klassen, Christine L.
AU - Degnim, Amy
AU - Flanagan, Eoin P.
N1 - Funding Information: Dr. Flanagan has served on advisory boards for Alexion, Genentech and Horizon Therapeutics. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. Dr. Flanagan was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. Dr. Flanagan has received funding from the NIH ( R01NS113828 ). Dr. Flanagan is a member of the medical advisory board of the MOG project. Dr. Flanagan is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. Funding Information: Dr. Flanagan has served on advisory boards for Alexion, Genentech and Horizon Therapeutics. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. Dr. Flanagan was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. Dr. Flanagan has received funding from the NIH (R01NS113828). Dr. Flanagan is a member of the medical advisory board of the MOG project. Dr. Flanagan is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports.
PY - 2022/1/15
Y1 - 2022/1/15
KW - Antibody
KW - Breast cancer
KW - Encephalomyelitis
KW - Myelitis
KW - Spinal cord
UR - http://www.scopus.com/inward/record.url?scp=85121102653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121102653&partnerID=8YFLogxK
U2 - 10.1016/j.jns.2021.120086
DO - 10.1016/j.jns.2021.120086
M3 - Letter
C2 - 34920159
AN - SCOPUS:85121102653
VL - 432
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
SN - 0022-510X
M1 - 120086
ER -